TrialHepatic medicine : evidence and research2025

The Effect of Liv.52 DS in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Pilot, Randomized, Double-Blind, Placebo-Controlled, Clinical Study.

Umesh Jalihal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.